ClinicalTrials.gg
CompletedNCT01589978Updated Jul 26, 2018Results posted

PROMUS Element Plus US Post-Approval Study

A Phase 4 interventional study of PROMUS Element Plus Coronary Stent System and Aspirin in Coronary Artery Disease, sponsored by Boston Scientific Corporation. Completed at 52 sites in United States. Per ClinicalTrials.gov, last updated 2018-07-26.

Sponsored by Boston Scientific Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,681
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing aspirin in Coronary Artery Disease — 8 open to participants now, 9 under way, 1 of them phase 3. Aspirin · Coronary Artery Disease.

Enrollment
11th of 53
2,681 · median 200
Started
2012
with 1 other
Phase 4
38 of 53
5 open now
Registered
24th of 53
by date
Lead sponsor
3 of 53
Boston Scientific Corporation

Among the 53 studies testing aspirin in Coronary Artery Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2012, is one of 38 in phase 4, and was the 24th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 53 studies testing aspirin in Coronary Artery Disease are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aspirin in Coronary Artery Disease, or all of them as a file.
02

Study summary

This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice. Patients will have symptomatic heart disease or documented silent ischemia. This is a prospective, open-label consecutively-enrolling study. Clinical follow-up is through 5 years. Approximately 2,689 patients are to be enrolled in up to 65 centers in the United States.

Read the detailed description

The wide-spread use of drug-eluting stents (DES) has evolved as standard of care in de novo lesions. The PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients with symptomatic heart disease or documented silent ischemia due to de novo lesions in native coronary arteries ≥2.25 mm to ≤4.00 mm in diameter in lesions ≤34 mm in length. The proposed study will compile real-world clinical outcomes data for the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice.

Patients enrolled in this study are expected to follow antiplatelet therapy recommendations per American College of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography and Interventions (SCAI) guidelines for percutaneous coronary intervention (PCI). Recommended medications include aspirin, which should be taken for 3 days prior to the procedure or as a peri-procedural loading dose and then continued indefinitely. Additionally, one of the following P2Y12 antagonists may be given in a peri-procedural loading dose and in a maintenance dose per physician discretion: clopidogrel, prasugrel, ticagrelor, or ticlopidine.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • drug-eluting stent
  • DES
  • atherosclerosis
  • everolimus
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The population will include consecutive, consented patients.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria in this all-comers study.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,681 participants (actual)

Study arms

  • Experimental
    PROMUS Element

    Subjects who receive the PROMUS Element everolimus-eluting coronary stent

    Device: PROMUS Element Plus Coronary Stent System · Drug: Aspirin · Drug: P2Y12 antagonist

Interventions

  • DevicePROMUS Element Plus Coronary Stent System

    PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).

    Also known as: PROMUS Element stent

  • Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.

    Also known as: Acetyl salicylic acid

  • Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI. * Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily) * Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling) * Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided. * Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)

    Also known as: PLAVIX (clopidogrel), TICLID (ticlopidine), EFFIENT (prasugrel), BRILINTA (ticagrelor)

06

What researchers measure

Primary outcomes

  1. Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients

    Cardiac death or myocardial infarction rate at 12 months post implantation in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and \<2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if rate meets the performance goal (3.2%)

    Time frame: 12 months

Secondary outcomes

  1. Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients

    ARC definite/probable ST rate in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and \<2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if the annual ST rate increase after the first year meets the performance goal (1.0%)

    Time frame: 12 months

  2. Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients

    DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  3. Rate of Longitudinal Stent Deformation

    Compression/elongation of a stent along its long axis resulting from interaction with an ancillary device (e.g., guide catheter) which catches the stent end or an internal stent strut; can occur with advancement or withdrawal of ancillary device. Under fluoroscopy, longitudinal compression usually results in increased strut density and elongation in decreased strut density ('pseudo-fracture'); both can occur in the same stent.

    Time frame: Index Procedure

  4. Major Adverse Cardiac Event Rate (MACE)

    Composite of cardiac death, myocardial infarction, and target vessel revascularization

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  5. Rate of Major Adverse Cardiac Events Related to the PROMUS Element Stent

    Composite of cardiac death, myocardial infarction, and target vessel revascularization related to the PROMUS Element stent

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  6. Myocardial Infarction (MI) Rate

    New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin \>upper limit of normal(ULN); if no new Q-waves total CK levels \>3×ULN (peri-percutaneous coronary intervention \[PCI\]) or \>2×ULN (spontaneous) with elevated CK-MB or troponin \>3×ULN (peri-PCI) or \>2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5×ULN

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  7. Rate of Myocardial Infarction (MI) Events Related to the PROMUS Element Stent

    New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin \>upper limit of normal(ULN); if no new Q-waves total CK levels \>3×ULN (peri-percutaneous coronary intervention \[PCI\]) or \>2×ULN (spontaneous) with elevated CK-MB or troponin \>3×ULN (peri-PCI) or \>2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5×ULN

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  8. Cardiac Death Rate

    Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  9. Rate of Cardiac Death Events Related to the PROMUS Element Stent

    Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  10. Target Vessel Revascularization (TVR) Rate

    Target vessel revascularization is defined as any attempted or successfully completed percutaneous or surgical revascularization of a target vessel.

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  11. Rate of Target Vessel Revascularization (TVR) Events Related to the PROMUS Element Stent

    Target vessel revascularization is defined as any attempted or successfully completed percutaneous or surgical revascularization of a target vessel.

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  12. Cardiac Death or Myocardial Infarction (MI) Rate

    See individual descriptions of events.

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  13. Rate of Cardiac Death or Myocardial Infarction Events Related to the PROMUS Element Stent

    See individual descriptions of events.

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  14. Target Vessel Failure (TVF) Rate

    Target vessel failure (TVF) is defined as any revascularization of the target vessel, myocardial infarction (MI) related to the target vessel, or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether MI or death was related to the target vessel it will be considered TVF.

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  15. Rate of Target Vessel Failure (TVF) Related to the PROMUS Element Stent

    Target vessel failure (TVF) is defined as any revascularization of the target vessel, myocardial infarction (MI) related to the target vessel, or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether MI or death was related to the target vessel it will be considered TVF.

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  16. All Death Rate

    All death includes cardiac death and non-cardiac death.

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  17. Non-cardiac Death Rate

    Non-cardiac death is defined as death not due to cardiac causes. Cardiac death is death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded.

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  18. All Death or Myocardial Infarction Rate

    See description of individual events.

    Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years

  19. Target Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients

    Any revascularization of the target vessel, myocardial infarction related to the target vessel, or death related to the target vessel. See individual components for descriptions. Statistical testing will determine if the rate meets the performance goal (12.6%)

    Time frame: 12 Months

  20. ARC ST Rate in PLATINUM-like Population.

    Using the Academic Research Consortium (ARC) definition, the (definite/probable) stent thrombosis (ST) rate in the PLATINUM-like\* population will be analyzed. Statistical testing will be used to determine if the annual increase after the first year in ST rates observed in PLATINUM-like patients meets the performance goal of 1.0% (expected rate of 0.4% + a delta of 0.6%).

    Time frame: Annually through 5 years

07

Results

Posted May 3, 2016

Participant flow

Participant flow — Overall Study
MilestonePROMUS Element Overall Population
Started2681
Completed2681
Not completed0

Outcome measures

PrimaryCardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients

Cardiac death or myocardial infarction rate at 12 months post implantation in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and \<2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if rate meets the performance goal (3.2%)

Time frame:
12 months
Reported as:
Number · percentage of patients
Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients
percentage of patientsPROMUS Element
Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients1.78
Statistical analysis
  • PROMUS Element · Chi-squared · p = <.0001
SecondaryDefinite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients

ARC definite/probable ST rate in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and \<2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if the annual ST rate increase after the first year meets the performance goal (1.0%)

Time frame:
12 months
Reported as:
Number · percentage of patients
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients
percentage of patientsPROMUS Element
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients0.3
SecondaryDefinite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients

DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients
percentage of patientsPROMUS Element
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients0.7
SecondaryRate of Longitudinal Stent Deformation

Compression/elongation of a stent along its long axis resulting from interaction with an ancillary device (e.g., guide catheter) which catches the stent end or an internal stent strut; can occur with advancement or withdrawal of ancillary device. Under fluoroscopy, longitudinal compression usually results in increased strut density and elongation in decreased strut density ('pseudo-fracture'); both can occur in the same stent.

Time frame:
Index Procedure
Reported as:
Number · stents
Rate of Longitudinal Stent Deformation
stentsPROMUS Element
Rate of Longitudinal Stent Deformation2
SecondaryMajor Adverse Cardiac Event Rate (MACE)

Composite of cardiac death, myocardial infarction, and target vessel revascularization

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Major Adverse Cardiac Event Rate (MACE)
percentage of patientsPROMUS Element
Major Adverse Cardiac Event Rate (MACE)6.9
SecondaryRate of Major Adverse Cardiac Events Related to the PROMUS Element Stent

Composite of cardiac death, myocardial infarction, and target vessel revascularization related to the PROMUS Element stent

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Rate of Major Adverse Cardiac Events Related to the PROMUS Element Stent
percentage of patientsPROMUS Element
Rate of Major Adverse Cardiac Events Related to the PROMUS Element Stent4.7
SecondaryMyocardial Infarction (MI) Rate

New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin \>upper limit of normal(ULN); if no new Q-waves total CK levels \>3×ULN (peri-percutaneous coronary intervention \[PCI\]) or \>2×ULN (spontaneous) with elevated CK-MB or troponin \>3×ULN (peri-PCI) or \>2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5×ULN

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Myocardial Infarction (MI) Rate
percentage of patientsPROMUS Element
Myocardial Infarction (MI) Rate1.1
SecondaryRate of Myocardial Infarction (MI) Events Related to the PROMUS Element Stent

New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin \>upper limit of normal(ULN); if no new Q-waves total CK levels \>3×ULN (peri-percutaneous coronary intervention \[PCI\]) or \>2×ULN (spontaneous) with elevated CK-MB or troponin \>3×ULN (peri-PCI) or \>2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5×ULN

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Rate of Myocardial Infarction (MI) Events Related to the PROMUS Element Stent
percentage of patientsPROMUS Element
Rate of Myocardial Infarction (MI) Events Related to the PROMUS Element Stent0.7
SecondaryCardiac Death Rate

Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Cardiac Death Rate
percentage of patientsPROMUS Element
Cardiac Death Rate1.4
SecondaryRate of Cardiac Death Events Related to the PROMUS Element Stent

Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Rate of Cardiac Death Events Related to the PROMUS Element Stent
percentage of patientsPROMUS Element
Rate of Cardiac Death Events Related to the PROMUS Element Stent1.3
SecondaryTarget Vessel Revascularization (TVR) Rate

Target vessel revascularization is defined as any attempted or successfully completed percutaneous or surgical revascularization of a target vessel.

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Target Vessel Revascularization (TVR) Rate
percentage of patientsPROMUS Element
Target Vessel Revascularization (TVR) Rate5.6
SecondaryRate of Target Vessel Revascularization (TVR) Events Related to the PROMUS Element Stent

Target vessel revascularization is defined as any attempted or successfully completed percutaneous or surgical revascularization of a target vessel.

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Rate of Target Vessel Revascularization (TVR) Events Related to the PROMUS Element Stent
percentage of patientsPROMUS Element
Rate of Target Vessel Revascularization (TVR) Events Related to the PROMUS Element Stent3.5
SecondaryCardiac Death or Myocardial Infarction (MI) Rate

See individual descriptions of events.

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Cardiac Death or Myocardial Infarction (MI) Rate
percentage of patientsPROMUS Element
Cardiac Death or Myocardial Infarction (MI) Rate2.3
SecondaryRate of Cardiac Death or Myocardial Infarction Events Related to the PROMUS Element Stent

See individual descriptions of events.

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Rate of Cardiac Death or Myocardial Infarction Events Related to the PROMUS Element Stent
percentage of patientsPROMUS Element
Rate of Cardiac Death or Myocardial Infarction Events Related to the PROMUS Element Stent1.8
SecondaryTarget Vessel Failure (TVF) Rate

Target vessel failure (TVF) is defined as any revascularization of the target vessel, myocardial infarction (MI) related to the target vessel, or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether MI or death was related to the target vessel it will be considered TVF.

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Target Vessel Failure (TVF) Rate
percentage of patientsPROMUS Element
Target Vessel Failure (TVF) Rate6.7
SecondaryRate of Target Vessel Failure (TVF) Related to the PROMUS Element Stent

Target vessel failure (TVF) is defined as any revascularization of the target vessel, myocardial infarction (MI) related to the target vessel, or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether MI or death was related to the target vessel it will be considered TVF.

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Rate of Target Vessel Failure (TVF) Related to the PROMUS Element Stent
percentage of patientsPROMUS Element
Rate of Target Vessel Failure (TVF) Related to the PROMUS Element Stent4.7
SecondaryAll Death Rate

All death includes cardiac death and non-cardiac death.

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
All Death Rate
percentage of patientsPROMUS Element
All Death Rate2.3
SecondaryNon-cardiac Death Rate

Non-cardiac death is defined as death not due to cardiac causes. Cardiac death is death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded.

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
Non-cardiac Death Rate
percentage of patientsPROMUS Element
Non-cardiac Death Rate0.9
SecondaryAll Death or Myocardial Infarction Rate

See description of individual events.

Time frame:
≤24 hours, 30 days, 180 days, annually through 5 years
Reported as:
Number · percentage of patients
All Death or Myocardial Infarction Rate
percentage of patientsPROMUS Element
All Death or Myocardial Infarction Rate3.2
SecondaryTarget Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients

Any revascularization of the target vessel, myocardial infarction related to the target vessel, or death related to the target vessel. See individual components for descriptions. Statistical testing will determine if the rate meets the performance goal (12.6%)

Time frame:
12 Months
Reported as:
Number · percentage of patients
Target Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients
percentage of patientsPROMUS Element
Target Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients3.26
SecondaryARC ST Rate in PLATINUM-like Population.

Using the Academic Research Consortium (ARC) definition, the (definite/probable) stent thrombosis (ST) rate in the PLATINUM-like\* population will be analyzed. Statistical testing will be used to determine if the annual increase after the first year in ST rates observed in PLATINUM-like patients meets the performance goal of 1.0% (expected rate of 0.4% + a delta of 0.6%).

Time frame:
Annually through 5 years
Reported as:
Number · percentage of participants
ARC ST Rate in PLATINUM-like Population.
percentage of participantsPROMUS Element Overall Population
ARC ST Rate in PLATINUM-like Population.0.0023
Statistical analysis
  • PROMUS Element Overall Population · Chi-squared · p = <.0001

Adverse events

Collected over Serious and non-serious adverse events were collected from the point of subject enrollment through primary endpoint (12 months).. Non-serious events are listed at a 0.1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PROMUS Element—780/2,681 (29.1%)5/2,681 (0.2%)
Most frequent serious events
Showing 10 of 344
Most frequent serious events
EventPROMUS Element
ANGINA PECTORISCardiac disorders120/2681
ANGINA UNSTABLECardiac disorders93/2681
NON-CARDIAC CHEST PAINGeneral disorders78/2681
CORONARY ARTERY DISEASECardiac disorders49/2681
CARDIAC FAILURE CONGESTIVECardiac disorders46/2681
PNEUMONIAInfections and infestations36/2681
ACUTE MYOCARDIAL INFARCTIONCardiac disorders33/2681
DYSPNOEARespiratory, thoracic and mediastinal disorders24/2681
ATRIAL FIBRILLATIONCardiac disorders23/2681
MYOCARDIAL INFARCTIONCardiac disorders22/2681
Most frequent other events
Most frequent other events
EventPROMUS Element
Myocardial InfarctionCardiac disorders5/2681

Baseline characteristics

Age, Continuous
Age, Continuous(years)PROMUS Element
Mean63.7 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)PROMUS Element
Female807
Male1874
Region of Enrollment
Region of Enrollment(participants)PROMUS Element
United States2681
Cardiac History
Cardiac History(participants)PROMUS Element
History of CAD1625
History of MI1409
History of CHF275
Stable Angina620
Unstable Angina1347
Silent Ischemia149
History of PCI1159
History of CABG457
Cardiac Risk Factors
Cardiac Risk Factors(participants)PROMUS Element
Smoking, Ever1600
Current Diabetic Mellitus989
Hyperlipidemia Requiring Medication2016
History of Hypertension Requiring Medication2077
Family History of CAD1625
Lesion Characteristics: Target Lesion Vessel
Lesion Characteristics: Target Lesion Vessel(lesions)PROMUS Element
Left Anterior Descending Artery1339
Circumflex Artery848
Right Coronary Artery1165
Left Main54
Graft199
Lesion Characteristics: Lesion Length
Lesion Characteristics: Lesion Length(mm)PROMUS Element
Mean17.0 ± 10.3
Lesion Characteristics: Reference Vessel Diameter
Lesion Characteristics: Reference Vessel Diameter(mm)PROMUS Element
Mean2.94 ± 0.51

1 further baseline measures are reported on the registry.

08

Study locations

52 sites
  • Huntsville Hospital - The Heart Center, PC
    Huntsville, Alabama 35801, United States
  • Springhill Medical Center
    Mobile, Alabama 36608, United States
  • NEA Baptist Memorial Hospital
    Jonesboro, Arkansas 72401, United States
  • St. Bernard's Medical Center
    Jonesboro, Arkansas 72401, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • Mercy General Hospital
    Sacramento, California 95819, United States
  • Christiana Hospital
    Newark, Delaware 19718, United States
  • Brandon Regional Hospital
    Brandon, Florida 33511, United States
  • North Florida Regional Medical Center
    Gainesville, Florida 32605, United States
  • Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Orlando Regional Medical Center
    Orlando, Florida 32806, United States
  • Bay Medical Center
    Panama City, Florida 32401, United States
  • Martin Memorial Health Systems - Martin Memorial Medical Center
    Stuart, Florida 34996, United States
  • Piedmont Hospital
    Atlanta, Georgia 30309, United States
  • Coliseum Medical Center
    Macon, Georgia 31217, United States
  • Redmond Regional Medical Center
    Rome, Georgia 30165, United States
  • Blessing Hospital
    Quincy, Illinois 62301, United States
  • IU Health North Medical Center
    Carmel, Indiana 46032, United States
  • Franciscan St. Francis Hospital
    Indianapolis, Indiana 46237, United States
  • Community Heart and Vascular Hospital
    Indianapolis, Indiana 46250, United States
  • St. Joseph Hospital
    Lexington, Kentucky 40504, United States
  • Cardiovascular Research, LLC
    Shreveport, Louisiana 71103, United States
  • Eastern Maine Medical Center
    Bangor, Maine 04401, United States
  • Cape Cod Hospital
    Hyannis, Massachusetts 02601, United States
  • Lakeland Hospitals at St. Joseph
    Saint Joseph, Michigan 49085, United States
  • Mercy Hospital
    Coon Rapids, Minnesota 55433, United States
  • North Memorial Medical Center
    Minneapolis, Minnesota 55422, United States
  • United Hospital - St. Paul Heart Clinic
    Saint Paul, Minnesota 55102, United States
  • Forest County General Hospital
    Hattiesburg, Mississippi 39401, United States
  • St. John's Regional Health Center (Springfield)
    Springfield, Missouri 65804, United States
  • Cox Medical Centers
    Springfield, Missouri 65807, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New York University Medical Center
    New York, New York 10011, United States
  • St. Elizabeth Medical Center
    Utica, New York 13501, United States
  • Novant Health Presbyterian Medical Center
    Charlotte, North Carolina 28204, United States
  • St. Francis Hospital
    Tulsa, Oklahoma 74136, United States
  • Doylestown Hospital
    Doylestown, Pennsylvania 18901, United States
  • Presbyterian University of Pennsylvania Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • University Medical Center-Greenville Memorial Hospital
    Greenville, South Carolina 29605, United States
  • St. Francis Health System - St. Francis Hospital
    Greenville, South Carolina 29607, United States
  • Grand Strand Regional Medical Center
    Myrtle Beach, South Carolina 29572, United States
  • Rapid City Regional Hospital
    Rapid City, South Dakota 57701, United States
  • Avera Heart Hospital of South Dakota
    Sioux Falls, South Dakota 57108, United States
  • South Austin Hospital
    Austin, Texas 78745, United States
  • VA North Texas Health Care System
    Dallas, Texas 75216, United States
  • Presbyterian Hospital of Dallas
    Dallas, Texas 75231, United States
  • University of Utah Hospital and Clinics
    Salt Lake City, Utah 84132, United States
  • Chippenham Medical Center
    Richmond, Virginia 23225, United States
  • Carilion Roanoke Memorial Hospital
    Roanoke, Virginia 24014, United States
  • Meriter Hospital
    Madison, Wisconsin 53713, United States
  • Marshfiled Clinic
    Weston, Wisconsin 55476, United States
09

References and documents

Publications

  • Batchelor WB, Damluji AA, Yong C, Fiuzat M, Barnett SD, Kandzari DE, Sherwood MW, Epps KC, Tehrani BN, Allocco DJ, Meredith IT, Lindenfeld J, O'Connor CM, Mehran R. Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries. Am Heart J. 2021 Jun;236:37-48. doi: 10.1016/j.ahj.2021.02.003. Epub 2021 Feb 24. PubMed 33636137 ↗
  • Kandzari DE, Amjadi N, Caputo C, Rowe SK, Williams J, Tamboli HP, Christen T, Allocco DJ, Dawkins KD. One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS]). Am J Cardiol. 2016 Feb 15;117(4):539-545. doi: 10.1016/j.amjcard.2015.11.043. Epub 2015 Dec 7. PubMed 26732420 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Aug 2014 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2012
First posted
May 2, 2012
Start
May 2012
Primary completionActual
Aug 2014
CompletionActual
Jun 2018
Results first posted
May 3, 2016
Last update
Jul 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01589978
Responsible party
Sponsor
First posted
May 2, 2012
Start date
May 2012
Primary completion
Aug 2014
Completion
Jun 2018
Results posted
May 3, 2016
Last update
Jul 26, 2018

Study contacts

Peter M Maurer, MPH
study director · Boston Scientific Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Clopidogrel

Start the discussion